Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide. The most recent global cancer burden estimated almost 760,000 deaths in 2022 alone. Notable advances over the past year in the management of HCC include new options in systemic therapy and exciting data regarding combinations with locoregional therapies. Adjuvant systemic therapy for resectable HCC remains disappointing, highlighting the need for further understanding of predictive biomarkers. Additional insight into optimal treatment of unique populations and continued development of novel therapeutics are also highlighted in this review.